Supporting Information

Diversiform Nanostructures Constructed from Tetraphenylethene and Pyrene-based Acid-Base Controllable Molecular Switching Amphiphilic [2]Rotaxanes with Tunable Aggregation-Induced Static Excimers

Reguram Arumugaperumal,^a Muthaiah Shellaiah,^a Venkatesan Srinivasadesikan,^{b,c} Kamlesh Awasthi,^{b,d} Kien Wen Sun,^a Ming-Chang Lin,^b Nobuhiro Ohta,^{b,d} and Wen-Sheng Chung^a*

^a Department of Applied chemistry, National Chiao Tung University, Hsinchu 300, Taiwan, R.O.C.

^b Department of Applied Chemistry and Institute of Molecular Science, National Chiao Tung University, Hsinchu 300, Taiwan, R.O.C.

^c Vignan's Foundation for Science, Technology and Research, Division Chemistry, Department of Sciences and Humanities, Vadlamudi, 522 213 Guntur, Andhra Pradesh, India.

^d Center for Emergent Functional Matter Science, National Chiao Tung University, Hsinchu 300, Taiwan, R.O.C.

*Author for Correspondence:


Prof. Wen-Sheng Chung Department of Applied Chemistry National Chiao Tung University Hsinchu, Taiwan (ROC) Tel: +886-3-5131517 Fax: +886-3-5723764 E-mail: <u>wschung@nctu.edu.tw</u>

Contents	Page Number
Synthesis overview and protocols	S3–S10
Supporting Figures and Tables	S11-S22
¹ H NMR, ¹³ C NMR and HRMS spectra	S22-S38
IR spectra	S38–S39
Supporting References	S40

Synthesis overview and protocols

Synthesis of S4

Compound S4 was synthesized according to the reported procedures.^{S1}




Scheme S1: Synthesis of S4 with reagents and conditions: (a) MeOH, NaBH₄, 0°C, 24 h, 63%;
(b) Con. HCl, MeOH, NH₄PF₆, H₂O, 70%.

To the solution of compound **S3** (3.32 g, 6.56 mmol) in MeOH (25 mL) was added conc. HCl to adjust pH < 2, and the solvent was then evaporated off under reduced pressure. The residue was suspended in acetone (25 mL). A saturated aqueous solution of NH₄PF₆ was added until the suspension became clear. The solvent was removed in vacuum, and water (50 mL) was added to the residue and the aqueous layer was extracted with DCM (3 × 50 mL). The combined organic layers were dried over anhydrous MgSO₄ and concentrated under reduced pressure to provide the pure compound **S4** as a yellow glassy solid (3 g, 70%).

Synthesis of DBA

Compound C2 was synthesized according to the reported procedures.⁵²




Scheme S2: Synthesis of DBA with reagents and conditions: (a) Con. HCl, MeOH, NH_4PF_6 , H_2O , 96%.

To the solution of compound **C2** (1.5 g, 3.77 mmol) in MeOH (25 mL) was added conc. HCl to adjust pH < 2, and the solvent was then evaporated off under reduced pressure. The residue was suspended in acetone (25 mL). A saturated aqueous solution of NH₄PF₆ was added until the suspension became clear. The solvent was removed in vacuum, and water (50 mL) was added to the residue and the aqueous layer was extracted with DCM (3 × 50 mL). The combined organic layers were dried over anhydrous MgSO₄ and concentrated under reduced pressure to provide the pure compound **DBA** as a white solid (2.25 g, 96%).¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 7.48 (s, 5H), 7.44 (d, *J* = 8.8 Hz, 2H), 7.08 (d, *J* = 8.8 Hz, 2H), 4.78 (d, *J* = 2.4 Hz 2H), 4.22 (d, *J* = 3.1 Hz, 2H), 4.20 (d, *J* = 4.5 Hz, 2H), 2.85 (t, *J* = 2.4 Hz, 1H) ppm; ¹³C NMR (125 MHz, CD₃CN) δ (ppm) = 160.1, 133.5, 132.2, 131.7, 131.3, 130.7, 124.9, 116.8, 116.7, 80.0, 77.7, 57.2, 52.9, 52.7. HRMS–ESI (m/z): [M –PF₆]⁺ calcd for C₁₇H₁₈NO, 252.1383; found, 252.1383.

Synthesis of Py-U


The following compounds of **1-Pyrenyl isocyanate** and **S5** were synthesized according to the reported procedures ^{S3, S4}



Scheme S3: Synthesis of Py-U with reagents and conditions: (a) trophosgene,Et₃N,toluene, 80 °C, 5h, 71%; (b) DCM, rt, overnight, 61%.

In a round-bottomed flask compound **S5** (0.424 g, 3.2 mmol) was dissolved in dry DCM and 1pyrenyl isocyanate (0.8 g, 3.26 mmol) added and stirred at room temperature for overnight. After that, the solvent was then removed under reduced pressure and the resulting crude compound purified by chromatography on silica gel (DCM/MeOH, 9.8/0.2) to provide the desired product **Py-U** as a light green powder. (0.750 g, 61 %).¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 8.35 (d, J = 8.3 Hz, 1H), 8.23–8.1 (m, 4H), 8.12 (d, J = 9.32 Hz, 1H), 8.08–8.01 (m, 3H), 7.73 (s, 1H), 5.74 (s, 1H), 3.69 (t, J = 4.8 Hz, 2H), 3.62 (t, J = 5.4 Hz, 2H), 3.45 (q, J = 5.5 Hz, 2H), 3.4 (t, J = 5.0 Hz, 2H) ppm; ¹³C NMR (125 MHz, CD₃CN) δ (ppm) = 158.1, 134.6, 133.3, 133.3, 133.0, 132.6, 130.3, 130.2, 129.4, 128.9, 128.7, 127.9, 127.6, 126.8, 126.6, 126.2, 126.1, 123.6, 122.9, 118.9, 71.5, 71.0, 52.1, 41.4. HRMS–ESI (m/z): [M+H]⁺ calcd for C₂₁H₂₀N₅O₂, 374.1612; found, 374.1619.

Synthesis of axle A1




Scheme S4. Synthesis of A1 with reagents and conditions: (a) NaAsc, CuSO₄•5H₂O, THF/H₂O (3:1), 24 hr, 63%.

Compound **S4** (0.3 g, 4.6 mmol) and **Py-U** (0.17 g, 4.6 mmol) were dissolved in THF/H₂O (v/v = 3:1, 40 mL) in a round-bottomed flask under an inert atmosphere. An aqueous solution of copper (II) sulphate pentahydrate (0.229 g, 0.92 mmol) and sodium ascorbate (0.364 g, 1.8 mmol) was added to the reaction mixture and allowed to stir at room temperature for overnight. Completion of the reaction was monitored by TLC (SiO₂). The solvent was removed under reduce pressure

and the crude product dissolved in DCM (100 mL). The organic phase was washed successively with an aqueous solution of NH₄Cl (2 × 30 mL) and H₂O (30 mL) and was separated, dried (MgSO₄) and evaporated. The crude product was purified by silica gel chromatography (DCM / MeOH, 9.8/0.2) to afford the pure compound **A1** as a pale white solid in 63 % yield. ¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 8.26–8.01 (m, 6H), 8.03–8.01 (m, 3H), 7.92 (s, 1H), 7.73 (s, 1H), 7.13 (d, J = 2.0 Hz, 2H) 7.12–7.10 (m, 4H), 7.08–7.03 (m, 3H), 7.01–6.91 (m, 10H), 6.85 (dd, J = 1.92, 6.5 Hz, 2H), 6.79 (dd, J = 2.0, Hz, 2H), 5.72 (t, J = 5.36 Hz, 1H), 5.08 (s, 2H), 4.54 (t, J = 4.8 Hz, 2H), 3.85 (t, J = 5.0 Hz, 2H), 3.65 (s, 2H), 3.60 (s, 2H), 3.4 (t, J = 5.4 Hz, 2H), 3.19 (q, J = 5.4 Hz, 2H) ppm; ¹³C NMR (125 MHz, CD₃CN) δ (ppm) = 159.4, 158.3, 145.0, 145.0, 144.8, 142.9, 134.0, 132.9, 132.3, 131.8, 129.9, 129.6, 129.3, 129.3, 128.8, 128.1, 128.0, 127.9, 127.8, 126.7, 126.5, 126.3, 126.3, 126.0, 123.8, 122.9, 118.9, 116.3, 71.2, 70.4, 62.7, 52.8, 52.5, 51.7, 41.3. HRMS–ESI (m/z): [M–PF₆–]⁺ calcd for C₅₈H₅₁N₆O₃, 879.4017; found, 879.4030.

Synthesis of control compound C1




Scheme S5. Synthesis of C1 with reagents and conditions: (a) NaAsc, CuSO₄•5H₂O, THF/H₂O (3:1), 24 hr, 43%.

Compound **DBA** (0.3 g, 0.75 mmol) and **Py-U** (0.283 g, 0.75 mol) were dissolved in THF/H₂O (v/v = 3:1, 40 mL) in a round-bottomed flask under an inert atmosphere. An aqueous solution of

copper (II) sulphate pentahydrate (0.377 g, 1.51 mmol) and sodium ascorbate (0.600 g, 3.02 mmol) was added to the reaction mixture and allowed to stir at room temperature for overnight. Completion of the reaction was monitored by TLC (SiO₂). The solvent was removed under reduce pressure and the crude product dissolved in DCM (100 mL). The organic phase was washed successively with an aqueous solution of NH_4Cl (2 × 30 mL) and H_2O (30 mL) and was separated, dried (MgSO₄) and evaporated. The crude product was purified by silica gel chromatography (DCM / MeOH, 9.8/0.2) to afford the pure compound C1 as a pale yellow solid in 43 % yield. ¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 8.39 (s, 1H), 8.24–8.14 (m, 4H), 8.09–7.98 (m, 4H), 7.94 (s, 1H), 7.74 (s, 1H) 7.35–7.30 (m, 5H), 7.02 (d, J = 8.72, 2H), 6.72 (d, J = 8.68, 2H), 5.73 (t, J = 5.36 Hz, 1H), 4.96 (s, 2H), 4.56 (t, J = 4.92 Hz, 2H), 3.89 (t, J = 5.12 Hz, 2H), 3.66 (s, 2H), 3.58–3.54 (m, 4H), 3.39 (q, J = 5.48 Hz, 2H) ppm; ¹³C NMR (125 MHz, CD₃CN) δ (ppm) = 158.7, 157.8, 145.0, 142.5, 134.8, 134.8, 134.7, 133.1, 132.6, 130.7, 129.8, 129.7, 129.2, 128.9, 128.3, 127.9, 127.5, 126.8, 126.6, 126.2, 124.4, 123.2, 122.8, 118.4, 71.5, 70.4, 62.9, 54.1, 53.5, 51.6, 41.2. HRMS-ESI (m/z): $[M-PF_6]^+$ calcd for C₃₈H₃₇N₆O₃, 625.2935; found, 625.2922. Synthesis of *t*-butylcalix[4]arene macrocycle S7.


The following compounds of **S6** and *t*-butylcalix[4]arene macrocycle **S7** were synthesized according to the reported procedures.^{S1}



Scheme S6. Synthesis of S7 with reagents and conditions: (a) K₂CO₃, ACN, reflux, 3 days, 70%.

A mixture of calix[4]arene (1.00 g, 1.54 mmol), compound **S6** (1.05 g, 1.54 mmol) and K₂CO₃ (0.426 g, 3.08 mmol) in dried acetonitrile (38 mL) was refluxed for 2 days. The reaction mixture was filtered and then concentrated under reduced pressure. The crude product was purified by column chromatography (SiO₂, DCM/MeOH = 9.8/0.2) to afford a white solid compound **S7** (1.06 g, 1.08 mmol, 70%). ¹H NMR (600 MHz, CD₃CN): $\delta_{\rm H}$ 8.12 (s, 2H), 7.23 (s, 4H), 7.16 (s, 4H), 6.94–6.92 (m, 4H), 4.38 (d, *J* = 12.6 Hz, 4H), 4.16–4.12 (m, 8H), 4.06–4.04 (m, 4H), 3.89–3.86 (m, 12H), 3.36 (d, *J* = 12.6 Hz, 4H), 1.22 (s, 18H), 1.17 (s, 18H).

Synthesis of [2]rotaxane P1-b.




Scheme S7. Synthesis of [2]rotaxane P1-b with reagents and conditions: (a) DCM, aq. NaOH (0.1M), 2 hr, 50%.

Preparation of [2]rotaxane P1-b.

[2]Rotaxane **P1** (100 mg, 0.049 mmol) was dissolved in dichloromethane (10 mL). NaOH (aq 0.1 M (5 mL) was added and the mixture was stirred vigorously at room temperature for 30

minutes. The layers were separated, the organic phase dried over MgSO₄, filtered off and concentrated affording the rotaxane **P1-b** (50 mg, 50%) as a white solid. ¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 8.77 (d, *J* = 8.32 Hz, 1H), 8.40 (s, 1H), 8.27– 8.02 (m, 5H), 7.99–7.87 (m, 6H), 7.72 (d, *J* = 9.68 Hz, 2H), 7.58 (s, 1H), 7.16 (d, *J* = 8.0 Hz, 2H), 7.09–6.95 (m, 14H), 6.89–6.77 (m, 10H), 6. 63 (s, 4H), 6.44 (s, 2H), 6.35 (s, 1H), 5.48 (s, 1H), 5.03 (s, 2H), 4.41–4.28 (m, 8H), 4.16–4.05 (m, 6H), 3.96–3.89 (m, 8H), 3.79–3.67 (m, 10H), 3.62–3.50 (m, 8H) 3.26 (d, *J* = 13.36 Hz, 4H), 1.31 (d, *J* = 3.12 Hz, 18H), 0.84 (s, 18H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ (ppm) = 157.8, 150.5, 149.7, 148.9, 143.7, 143.7, 132.8, 132.0, 131.8, 131.2, 131.0, 131.0, 130.8, 129.7, 129.2, 128.1, 128.1, 127.9, 127.7, 127.6, 127.5, 127.4, 127.2, 126.4, 126.4, 126.3, 126.0, 125.6, 125.4, 125.3, 125.2, 125.1, 124.9, 124.6, 123.8, 121.4, 121.3, 114.6, 114.5, 114.0, 71.2, 71.1, 70.5, 70.2, 70.1, 69.8, 69.6, 69.3, 68.8, 61.7, 52.5, 50.1, 33.9, 33.7, 31.7, 31.4, 31.2, 31.0, 30.8. HRMS–ESI (m/z): [M+H]⁺ calcd for C₁₂₀H₁₃₃N₆O₁₃, 1865.9925; found, 1865.9983.

Synthesis of [2]rotaxane P2-b.



Scheme S8. Synthesis of [2]rotaxane P2-b with reagents and conditions: (a) DCM, aq. NaOH (0.1 M), 2 hr, 60%.

Preparation of [2]rotaxane P2-b.

[2]Rotaxane P2 (100 mg, 0.046 mmol) was dissolved in dichloromethane (10 mL). NaOH (aq 0.1 M (5 mL) was added and the mixture was stirred vigorously at room temperature for 30 minutes. The layers were separated, the organic phase dried over MgSO₄, filtered off and concentrated affording the rotaxane **P2-b** (65 mg, 60%) as a white solid. ¹H NMR (400 MHz, CD₃CN): $\delta_{\rm H}$ 9.10 (s, 1H), 8.44 (d, J = 8.36 Hz, 1H), 8.25–8.16 (m, 5H), 8.10–8.03 (m, 4H), 7.81 (s, 1H), 7.36 (d, J = 14.8 Hz, 2H), 7.20–7.03 (m, 29H), 6.97 (d, J = 7.88 Hz, 2H), 6.89–6.85 (m, 4H), 5.83 (s, 1H), 5.04 (s, 2H), 4.26 (t, J = 6.52 Hz, 2H), 4.16 (dd, J = 4.96, 12.8 Hz, 4H), 4.08– 3.98 (m, 10H), 3.78 (s, 3H), 3.75 (t, J = 5.48 Hz, 2H), 3.69–3.68 (m, 4H), 3.61 (d, J = 5.12 Hz, 5H), 3.55 (s, 7H) 3.51 (d, J = 5.44 Hz, 2H), 3.41 (s, 2H), 3.32–3.24 (m, 6H), 1.22 (d, J = 1.92 Hz, 18H), 1.06 (s,18H) ppm; ¹³C NMR (125 MHz, CD₃CN) δ (ppm) = 157.8, 151.2, 151.0, 149.4, 149.3, 145.4, 144.3, 144.1, 143.7, 142.6, 142.5, 141.2, 134.7, 134.7, 134.6, 133.1, 132.5, 132.4, 132.3, 131.0, 129.3, 129.1, 129.0, 128.9, 128.8, 128.7, 128.0, 128.0, 127.9, 127.7, 127.2, 127.1, 127.0, 126.9, 126.7, 126.2, 123.2, 122.8, 122.7, 118.9, 116.3, 114.0, 77.5, 72.2, 72.0, 71.7, 71.4, 70.8, 69.8, 68.6, 60.3, 54.5, 53.6, 53.3, 35.4, 35.2, 35.2, 32.5, 32.4, 32.3, 32.1, 31.9. HRMS-ESI (m/z): $[M]^+$ calcd for $C_{121}H_{135}N_6O_{13}$, 1880.0235; found, 1880.0082.




Figure S1. ¹H NMR spectra (400 MHz, 298 K, CD_3CN) of (a) [2]rotaxane **P2**, (b) deprotonation with addition of one equivalent NaOH to sample a, and (c) further addition of four equivalent of TFA to sample b.




Figure S2. UV-vis absorption spectra of all [2]rotaxanes and its precursors in pure THF solvent (10 μ M).




Figure S3. UV-vis absorption spectra of [2]rotaxanes (a) C1 and (b) A1 in THF/water mixtures (10 μ M) with different water fractions (f_w).




Figure S4. UV-vis absorption spectra of [2]rotaxanes (a) **P1** and (b) **P2** in THF/water mixtures (10 μ M) with different water fractions (f_w).




Figure S5.UV-vis absorption spectra of [2]rotaxanes (a) **P1-b** and (b) **P2-b** in THF/water mixtures (10 μ M) with different water fractions (f_w).




Figure S6. Fluorescence spectra of axle **A1** in THF/water mixtures (10 μ M) with different water fractions (f_w) ($\lambda_{ex} = 320$ nm); Inset figures: fluorescence photographs in THF/water mixtures with various water fractions (f_w) taken under UV illumination ($\lambda_{ex} = 365$ nm).




Figure S7. Fluorescence spectra of precursor **Py-U** in THF/water mixtures (10 μ M) with different water fractions (f_w) ($\lambda_{ex} = 320$ nm).




Figure S8. Fluorescence spectra of C1 in THF/water mixtures (10 μ M) with different water fractions (f_w) ($\lambda_{ex} = 320$ nm).




Figure S9. Plots of fluorescence intensity versus water fraction of (a) axle A1, (b) C1 in THF/water mixture with different water fractions (from 0 to 99%).




Figure S10. Plots of fluorescence intensity versus water fraction of [2]rotaxanes (a) **P1**, (b) **P2**, (c) **P1-b**, and (d) **P2-b** in THF/water mixture with different water fractions (from 0 to 99%).




Figure S11. Normalized excitation spectra of (a) **C1** and (b) **A1** were monitored at 395 nm and 475 nm; $f_w = 0\%$ (black dash line); (a) $f_w = 99\%$ and (b) $f_w = 80\%$ (red solid line) in THF/water mixtures (10 µM).




Figure S12. Normalized excitation spectra of [2]rotaxanes (a) **P1-b** and (b) **P2-b** were monitored at 395 nm, $f_w = 0\%$ (black dash line) and 475 nm, $f_w = 90\%$ (red solid line) in THF/water mixtures (10 μ M).

Table S1. Optical properties of axle A1 and [2]rotaxanes P1, P2, P1-b and P2-b (10 μ M) in AIE state (in THF/water mixture at water fraction $f_w = 90\%$). AIE states using 9,10 diphenylanthracene ($\Phi_F = 90\%$ in cyclohexane) as standard.^{S5}

λ_{abs} (nm)		λ _{emi} (nm)		Φ _F AIE state
Compounds	Solution	Solution	AIE state	
A1	344	394/414	480	0.012
P1	344	394/414	486	0.023
P2	349	393/415	478	0.021
P1-b	350	394/414	480	0.017
Р2-b	342	393/414	477	0.012




Figure S13. Powder X-ray diffraction patterns at room temperature of compounds (a) axle A1,(b) C1, (c) P1, and (d) P2.

Table S2: The results of frontier molecular orbital calculations and TD-DFT computed at B3LYP/6-31G (d,p)//HF level in gas phase.

[2]rotaxanes	Oscillator Strength (f)	Band Gap (eV)	Electronic excitation
P1	0.2079	3.74	HOMO to LUMO+3
P2	0.0012	1.83	HOMO to LUMO+1
P1-b	0.3274	4.52	HOMO-4 to LUMO+1
Р2-b	0.004	3.48	HOMO-2 to LUMO




Figure S14. Geometries optimized at B3LYP/6-31G (d,p)//HF level of axle A1.




Figure S15. Frontier Molecular Orbitals of [2]rotaxanes **P1** and **P1-b** at the B3LYP/6-31G (d,p)//HF level in the gas phase.




Figure S16. Frontier Molecular Orbitals of [2]rotaxanes **P2** and **P2-b** at the B3LYP/6-31G (d,p)//HF level in the gas phase.




Figure S17. FE-SEM images of [2]rotaxanes (a) **P1**, (b) **P2**, (c) **P1-b**, and (d) **P2-b** in THF (10 μ M). Scale bar for figures a, b, c, and d was 1 μ m.




Figure S18. AFM images of [2]rotaxanes P1 and P1-b in THF/water mixture (1 μ M) with various water fractions (f_w): (a) 70% of P1, (b) 80% of P1, (c) 70% of P1-b, and (d) 90% of P1-b. Scale bar for figures a = 1 μ m; b, c, and d is 2 μ m.




Figure S19. The particle size distribution of [2]rotaxanes **P1** and **P1-b** in THF/water mixtures (a) at 70% f_w of **P1**, (b) at 80% f_w of **P1**, (c) at 70% f_w of **P1-b**, and (d) at 90% f_w of **P1-b**.




Figure S20. The particle size distribution of [2]rotaxanes **P2** and **P2-b** in THF/water mixtures (a) at 70% f_w of **P2**, (b) at 90% f_w of **P2**, (c) at 70% f_w of **P2-b**, and (d) at 90% f_w of **P2-b**.




Figure S21. Fluorescence microscopy images of MRC-5 live cells incubated with [2]rotaxanes **P1-b** and **P2-b** in DMSO (10 μ m); (a) Fluorescence images after cells were incubated for 5 hr (b) corresponding bright field images (c) overlay images of MRC-5. Scale bar is 50 μ m.




Figure S22. ¹H NMR (400 MHz, CD₃CN) spectrum of compound DBA




Figure S23. ¹³C NMR (125 MHz, CD₃CN) spectrum of compound DBA




Figure S24. HRMS ESI (+)-MS spectrum of compound DBA.




Figure S25. ¹H NMR (400 MHz, CD₃CN) spectrum of compound **Py-U**.




Figure S26. ¹³C NMR (125 MHz, CD₃CN) spectrum of compound Py-U.




Figure S27. HRMS ESI (+)-MS spectrum of compound Py-U.




Figure S28. ¹H NMR (400 MHz, CD₃CN) spectrum of compound A1.




Figure S29. ¹³C NMR (125 MHz, CD₃CN) spectrum of compound A1.




Figure S30. HRMS ESI (+)-MS spectrum of compound A1.




Figure S31. 2D-COSY spectrum (500 MHz, 298 K, CD₃CN) of compound A1.




Figure S32. ¹H NMR (400 MHz, CD₃CN) spectrum of compound C1.




Figure S33. ¹³C NMR (125 MHz, CD₃CN) spectrum of compound C1.




Figure S34. HRMS ESI (+)-MS spectrum of compound C1.




Figure S35. ¹H NMR (400 MHz, CD₃CN) spectrum of compound **S7**.




Figure S36. ¹H NMR (400 MHz, CD₃CN) spectrum of [2]rotaxane P1.




Figure S37. ¹³C NMR (125 MHz, CD₃CN) spectrum of [2]rotaxane P1.




Figure S38. HRMS ESI (+)-MS spectrum of [2]rotaxane P1.




Figure S39. 2D-COSY spectrum (500 MHz, 298 K, CD₃CN) of [2]rotaxane P1.




Figure S40. 2D ROESY spectrum (600 MHz, 298 K, CD₃CN) of [2]rotaxane P1.




Figure S41. ¹H NMR (400 MHz, CD₃CN) spectrum of [2]rotaxane P2.




Figure S42. ¹³C NMR (125 MHz, CD₃CN) spectrum of [2]rotaxane P2.




Figure S43. HRMS ESI (+)-MS spectrum of [2]rotaxane P2.




Figure S44. 2D-COSY spectrum (500 MHz, 298 K, CD₃CN) of [2]rotaxane P2.




Figure S45. 2D ROESY spectrum (600 MHz, 298 K, CD₃CN) of [2]rotaxane P2.




Figure S46. ¹H NMR (400 MHz, CDCl₃) spectrum of [2]rotaxane P1-b.




Figure S47. ¹³C NMR (125 MHz, CDCl₃) spectrum of [2]rotaxane P1-b.




Figure S48. HRMS ESI (+)-MS spectrum of [2]rotaxane P1-b.




Figure S49. 2D ROESY spectrum (600 MHz, 298 K, CDCl₃) of [2]rotaxane P1-b.




Figure S50. ¹H NMR (400 MHz, CD₃CN) spectrum of [2]rotaxane P2-b.




Figure S51. ¹³C NMR (125 MHz, CD₃CN) spectrum of [2]rotaxane P2-b.




Figure S52. HRMS ESI (+)-MS spectrum of [2]rotaxane P2-b.







Figure S53. 2D ROESY spectrum (600 MHz, 298 K, CD₃CN) of [2]rotaxane P2.



Figures S54. FTIR spectrum of compound A1.



Figures S55. FTIR spectra of compounds (a) P1 and (b) P1-b.



Figures S56. FTIR spectra of compounds (a) P2 and (b) P2-b.

References

- (S1) Arumugaperumal, R.; Raghunath, P.; Lin, M.-C.; Chung, W.-S. Distinct Nanostructures and Organogel Driven by Reversible Molecular Switching of a Tetraphenylethene-Involved Calix[4]arene-Based Amphiphilic [2]Rotaxane. *Chem. Mater.* 2018, 30, 7221–7233.
- (S2) Ge, Z.; Hu, J.; Huang, F.; Liu, S., Responsive Supramolecular Gels Constructed by Crown Ether Based Molecular Recognition. *Angew. Chem. Int. Ed.* 2009, 48, 1798–1802.
- (S3) Byrne, S.; Mullen, K. M., Urea and Thiourea Based Anion Receptors in Solution and on Polymer Supports. *Supramol. Chem.* 2018, *30*, 196–205.
- (S4) Chouhan, G.; James, K. CuAAC Macrocyclization: High Intramolecular Selectivity through the Use of Copper-Tris(triazole) Ligand Complexes. Org. Lett. 2011, 13, 2754–2757.
- (S5) Chang, Z.; Jiang, Y.; He, B.; Chen, J.; Yang, Z.; Lu, P.; Kwok, H. S.; Zhao, Z.; Qiu, H.; Tang, B. Z. Aggregation-Enhanced Emission and Efficient Electroluminescence of Tetraphenylethene-Cored Luminogens. *Chem. Commun.* **2013**, *49*, 594–596.